LABT ▲ +5.3% - Lakewood-Amedex Biotherapeutics, Inc. $LABT - Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers Lakewood-Amedex Biotherapeutics received institutional review board approval and confirmed clinical site readiness to begin its Phase 2a trial of Nu-3 for infected diabetic foot ulcers, moving the stock up 5.3%. The regulatory clearance to advance the candidate into human testing represents a key milestone that typically strengthens investor confidence in the company's development pipeline. 18-SEP-2026 08:16 AM ET